News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
689,833 Results
Type
Article (54962)
Company Profile (272)
Press Release (634599)
Multimedia
Podcasts (106)
Webinars (13)
Section
Business (195969)
Career Advice (2829)
Deals (35471)
Drug Delivery (121)
Drug Development (83076)
Employer Resources (171)
FDA (16938)
Job Trends (15921)
News (341850)
Policy (34585)
Tag
2024 BioCapital Digital (9)
2024 BioForest Digital (5)
2024 BioForest Standard (1)
2024 BioMidwest Digital (6)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (6)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (16)
2024 Biotech Beach Digital (11)
2024 Biotech Beach Standard (7)
2024 Genetown Digital (3)
2024 Genetown Standard (6)
2024 Lone Star Bio Digital (7)
2024 Pharm Country Digital (3)
2024 Pharm Country Standard (3)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (6)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (1)
2026 Genetown Standard (1)
2026 Pharm Country Standard (2)
Academia (2872)
Accelerated approval (6)
Adcomms (29)
Allergies (91)
Alliances (49756)
ALS (96)
Alzheimer's disease (1452)
Antibody-drug conjugate (ADC) (150)
Approvals (16908)
Artificial intelligence (285)
Autoimmune disease (28)
Automation (16)
Bankruptcy (359)
Best Places to Work (11916)
BIOSECURE Act (21)
Biosimilars (119)
Biotechnology (161)
Bladder cancer (83)
Brain cancer (31)
Breast cancer (296)
Cancer (2358)
Cardiovascular disease (200)
Career advice (2383)
Career pathing (34)
CAR-T (167)
Cell therapy (458)
Cervical cancer (20)
Clinical research (67572)
Collaboration (889)
Compensation (313)
Complete response letters (30)
COVID-19 (2830)
CRISPR (46)
C-suite (256)
Cystic fibrosis (107)
Data (2208)
Decentralized trials (2)
Denatured (32)
Depression (52)
Diabetes (292)
Diagnostics (6511)
Digital health (19)
Diversity (7)
Diversity, equity & inclusion (40)
Drug discovery (125)
Drug pricing (122)
Drug shortages (32)
Duchenne muscular dystrophy (100)
Earnings (75942)
Editorial (43)
Employer branding (22)
Employer resources (150)
Events (100146)
Executive appointments (755)
FDA (18210)
Featured Employer (46)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (771)
Gene editing (113)
Generative AI (27)
Gene therapy (339)
GLP-1 (829)
Government (4804)
Grass and pollen (6)
Guidances (54)
Healthcare (19143)
Huntington's disease (25)
IgA nephropathy (31)
Immunology and inflammation (143)
Indications (29)
Infectious disease (2989)
Inflammatory bowel disease (142)
Inflation Reduction Act (9)
Influenza (55)
Intellectual property (101)
Interviews (523)
IPO (15766)
IRA (48)
Job creations (4413)
Job search strategy (1995)
Kidney cancer (11)
Labor market (34)
Layoffs (540)
Leadership (23)
Legal (8182)
Liver cancer (81)
Lung cancer (339)
Lymphoma (154)
Machine learning (7)
Management (60)
Manufacturing (325)
MASH (71)
Medical device (13389)
Medtech (13394)
Mergers & acquisitions (20227)
Metabolic disorders (768)
Multiple sclerosis (86)
NASH (23)
Neurodegenerative disease (110)
Neuropsychiatric disorders (33)
Neuroscience (2039)
NextGen: Class of 2025 (6948)
Non-profit (4879)
Northern California (2513)
Now hiring (36)
Obesity (416)
Opinion (262)
Ovarian cancer (77)
Pain (94)
Pancreatic cancer (84)
Parkinson's disease (158)
Partnered (21)
Patents (235)
Patient recruitment (109)
Peanut (50)
People (58152)
Pharmaceutical (87)
Pharmacy benefit managers (21)
Phase I (20961)
Phase II (29539)
Phase III (22468)
Pipeline (1210)
Policy (165)
Postmarket research (2759)
Preclinical (8552)
Press Release (65)
Prostate cancer (110)
Psychedelics (36)
Radiopharmaceuticals (245)
Rare diseases (418)
Real estate (6215)
Recruiting (70)
Regulatory (23824)
Reports (35)
Research institute (2543)
Resumes & cover letters (432)
Rett syndrome (5)
RNA editing (4)
RSV (50)
Schizophrenia (79)
Series A (137)
Series B (89)
Service/supplier (13)
Sickle cell disease (57)
Southern California (2274)
Special edition (17)
Spinal muscular atrophy (158)
Sponsored (28)
Startups (3763)
State (2)
Stomach cancer (15)
Supply chain (75)
Tariffs (43)
The Weekly (72)
United States (21984)
Vaccines (797)
Venture capitalists (44)
Weight loss (295)
Women's health (33)
Worklife (19)
Date
Today (200)
Last 7 days (875)
Last 30 days (2649)
Last 365 days (32345)
2025 (10334)
2024 (34619)
2023 (39506)
2022 (50358)
2021 (54986)
2020 (54381)
2019 (48035)
2018 (36865)
2017 (33925)
2016 (33467)
2015 (38107)
2014 (30416)
2013 (25508)
2012 (27393)
2011 (28022)
2010 (25515)
Location
Africa (976)
Alabama (56)
Alaska (7)
Arizona (184)
Arkansas (14)
Asia (42131)
Australia (6936)
California (5915)
Canada (1870)
China (524)
Colorado (267)
Connecticut (261)
Delaware (127)
Europe (94105)
Florida (834)
Georgia (189)
Hawaii (1)
Idaho (59)
Illinois (542)
India (27)
Indiana (311)
Iowa (9)
Japan (160)
Kansas (104)
Kentucky (26)
Louisiana (11)
Maine (68)
Maryland (858)
Massachusetts (4149)
Michigan (211)
Minnesota (389)
Mississippi (2)
Missouri (85)
Montana (26)
Nebraska (25)
Nevada (56)
New Hampshire (69)
New Jersey (1621)
New Mexico (31)
New York (1675)
North Carolina (1000)
North Dakota (9)
Northern California (2513)
Ohio (194)
Oklahoma (13)
Oregon (39)
Pennsylvania (1256)
Puerto Rico (13)
Rhode Island (33)
South America (1338)
South Carolina (21)
South Dakota (1)
Southern California (2274)
Tennessee (101)
Texas (828)
Utah (190)
Virginia (155)
Washington D.C. (65)
Washington State (543)
West Virginia (3)
Wisconsin (54)
689,833 Results for "maat pharma sa".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
MaaT Pharma Presents Preclinical Data at AACR Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity of MaaT034
April 28, 2025
·
5 min read
Press Releases
MaaT Pharma Announces Positive Safety Interim Analysis from DSMB for Phase 2b Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT
April 8, 2025
·
4 min read
Press Releases
MaaT Pharma To Present New Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies
March 31, 2025
·
5 min read
Press Releases
MaaT Pharma Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for MaaT013
March 11, 2025
·
6 min read
Press Releases
MaaT Pharma Announces Initiation of Coverage of its Stock by H.C. Wainwright & Co
April 7, 2025
·
2 min read
Press Releases
MaaT Pharma Completes a Capital Increase of €13 Million with Historical Shareholders and Announces 2024 Annual Results
March 27, 2025
·
20 min read
Press Releases
MaaT Pharma Announces Positive Outcomes from Final DSMB Meeting for Pivotal Phase 3 Clinical Trial Evaluating MaaT013 in Acute Graft-versus-Host Disease
March 18, 2025
·
6 min read
Autoimmune disease
MaaT Clears Phase III in GVHD, Eyes European Submission By Midyear
MaaT013 in 2022 was put under clinical hold by the FDA, which cited safety and efficacy concerns with the sample-pooling method used to produce the investigational therapy. The hold was lifted in April 2023.
January 9, 2025
·
2 min read
·
Tristan Manalac
Press Releases
MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT
January 21, 2025
·
4 min read
MaaT Pharma Presents Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies
MaaT Pharma (EURONEXT: MAAT – the “Company”) presented new in vitro data characterizing the metabolites produced by MaaT034 and their impact on immune modulation at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, California.
April 8, 2024
·
3 min read
1 of 68,984
Next
